Market Performance
While the broader stock market today traded under pressure, Sudarshan Pharma share price told a very different story.
On Thursday, February 5, the small-cap stock, trading under ₹50, locked in its 10% upper circuit at ₹23.10. This sharp move came even as benchmark indices like the Sensex and Nifty 50 slipped nearly 0.5%, tracking weak global cues and ongoing concerns around AI-led disruptions in global technology markets.
What stood out was the contrast.
While the market struggled, this pharma counter stayed firmly in the green.
This session marked:
- Second consecutive day of hitting an upper circuit
- Third straight session of gains
- Over 17% rise in just 3 trading sessions
A day earlier, on February 4, the stock had already hit a 5% upper circuit at ₹21, setting the tone for Thursday’s move.
Main News
The recent surge may look sharp, but it comes after a long period of pressure.
Over the past year, Sudarshan Pharma share price has seen significant declines:
- Down over 40% in the last 1 year
- Down 24% in the last 6 months
- Down 19% in the last 3 months
- Down 12% in the last 1 month
Against this backdrop, the current rally stands out even more.
After months of steady erosion, the stock has suddenly found momentum, even as the wider stock market today struggled to find direction.
Company Financials
Recent financial numbers provide important context to the price movement.
Quarterly Performance – Q3FY26
- Net Sales: ₹168.01 crore
- Up 16% year-on-year compared with Q3FY25
- Net Profit: ₹4.36 crore
- Jumped 51% from the same quarter last year
Nine-Month Performance – FY26
- Net Sales: ₹482.14 crore
- Growth of 40% versus 9MFY25
- Net Profit: ₹12.58 crore
- Increase of 67% year-on-year
Full-Year Performance – FY25
- Net Sales: ₹505 crore
- Up 9% compared with FY24
- Net Profit: ₹16 crore
- Rise of 45% year-on-year
These numbers show steady improvement across periods, particularly at the profit level, even as market volatility remained high.
Business Update: Global Expansion
Away from the numbers, the company has also taken a strategic step to expand its global footprint.
Sudarshan Pharma incorporated a wholly owned subsidiary in Poland, named:
Sudarshan Pharma Company Poland Limited Liability, headquartered in Warsaw.
Key details:
- Board approval received: February 2025
- Investment amount: PLN 5,000
- Equity stake: 100% ownership
The subsidiary will focus on:
- Manufacturing of chemicals, fertilisers, and plastics
- Wholesale distribution of pharmaceutical products
This move is aimed at strengthening the company’s presence in European markets and supporting expansion in the global chemical and agrochemical space.
Company Overview
Sudarshan Pharma operates across multiple segments, including:
- Manufacturing of API
- Jobwork manufacturing for pharmaceutical products
- Trading in chemicals and solvents within India
- Presence in the speciality chemicals business
This diversified operational base forms the core of its business activities.
Summary
In a session where the stock market today remained weak, Sudarshan Pharma share price stood out by hitting a 10% upper circuit at ₹23.10.
Despite sharp declines over the past year, the stock has now logged three straight sessions of gains, backed by improved financial performance and steady business developments. Strong growth in net sales and net profit across quarterly, nine-month, and full-year periods adds important context to the recent price action.
As markets remain volatile, Sudarshan Pharma’s latest move highlights how individual stocks can move sharply, even when broader indices struggle for direction.
Source: Livemint
Easy & quick
Leave A Comment?